On October 22, 2026, the biotech giant Moderna experienced its most dramatic single-day price movement since the August rally that had propelled the stock to record highs. A premature circulation of data from its late-stage melanoma vaccine trial caused the shares to plunge as much as 26% intraday, ultimately closing down more than 17%. The episode erased roughly $17 billion of market capitalisation within hours, underscoring how fragile biotech valuations can be when investors confront unconfirmed information.
Leak triggers an abrupt market correction
The flash crash unfolded after the personalized mRNA vaccine—developed in partnership with Merck and intended to complement the immunotherapy Keytruda—was reported in a non-official channel. Merck confirmed that the results had indeed been released ahead of schedule, and the full dataset is slated for presentation on Saturday at the European Society for Medical Oncology (ESMO) meeting in Madrid. While the leaked figures still indicated a positive efficacy signal, the market reaction was fierce because the stock had surged nearly fourfold from mid-August, when the trial first met its primary endpoint.
Moderna’s August surge and ensuing volatility
On August 19, 2026, Moderna’s share price vaulted 177% to close at $174.38 after the company announced that the melanoma vaccine met its primary goals. The rally continued through the summer, reaching an all-time high on October 20, the day after the historic August close. The October 22 dip brought the price within 4% of that August peak before buying pressure halted the decline. Analysts note that a sustained breach below the $174 threshold could redirect attention to the $116 level, where the stock opened on the record-dropping day.
What the leaked numbers actually reveal
According to the early leak, the vaccine reduced the combined risk of disease recurrence or death by 42% when used alongside Merck’s Keytruda. A smaller, earlier study using a different patient cohort had reported a 49% reduction, but the two datasets are not directly comparable. The 42% figure, although still encouraging, fell short of the market’s inflated expectations built on the August announcement. Nevertheless, oncologists emphasised that extending disease-free survival represents a meaningful advance for patients with advanced melanoma.
Implications for other cancer indications
The success of the intismeran autogene vaccine could pave the way for similar mRNA-based, patient-specific therapies targeting other tumour types. The approach leverages the same mRNA platform that enabled rapid COVID-19 vaccine development, designing a bespoke sequence for each patient’s tumour-specific neoantigens. Experts remain cautious, however, about how broadly the technology can be scaled across diverse cancers, citing manufacturing complexity and the need for robust clinical validation.
Broader market ripple effects and upcoming outlook
While Moderna’s shares stumbled, the wider biotech sector recorded modest gains. Companies such as Eli Lilly added more than $33 billion in market value—roughly double the loss incurred by Moderna—while Johnson & Johnson and Pfizer also posted modest upticks. The iShares Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) moved only slightly, tracking the overall S&P 500 trend. Merck’s stock dipped nearly 4% before recouping half of the loss, reflecting its position as the dominant partner with a more diversified oncology portfolio.
Investors will be watching the official ESMO presentation closely. The full dataset is expected to detail efficacy across risk strata, safety outcomes, and any signals that could influence regulatory pathways. A robust confirmation could reignite the rally and restore confidence in Moderna’s oncology pipeline, while a muted result might prolong the current volatility and prompt a reassessment of the company’s valuation multiples.
